

Microbiology

Standard	Guidance
<p>The following Microbiology standards are applicable to the subspecialty testing categories as follows: Bacteriology (MB S1-S11); Mycobacteriology (MB S1-S9); Mycology (MB S1-S11); Parasitology (MB S6, MB S8-S9); Virology (MB S1, MB S6, MB S8-S11).</p>	
<p>The following specialty sustaining standards of practice and applicable general system standards shall be incorporated into the laboratory's quality management system, where applicable to the scope of services provided. Effective May 1, 2011.</p>	
<p>Microbiology Sustaining Standard of Practice 1 (MB S1): Quality Control Stock Cultures</p> <p>The laboratory shall maintain stock cultures for all quality control procedures.</p>	<p>Maintenance of stock cultures should be standardized in a manner that minimizes the opportunity for contamination or alteration of relevant characteristics. Stock cultures should consist of low-passage material rather than laboratory-adapted high passage material.</p> <p>Validated patient isolates, proficiency testing specimens, or commercially prepared controls may be used unless otherwise required by manufacturer. American Type Culture Collection (ATCC) controls are not required, except for use in susceptibility testing.</p>

Microbiology

Standard	Guidance
<p>Microbiology Sustaining Standard of Practice 2 (MB S2): Commercial Medium</p> <p>Each lot or shipment of commercially prepared media shall be tested:</p> <ul style="list-style-type: none"> a) on-site for growth, selectivity, and/or inhibition and biochemical responses; or, b) by the manufacturer in accordance with established criteria. Quality control checks for sterility, growth, selectivity and/or inhibition and biochemical responses need not be retested by the user provided that: <ul style="list-style-type: none"> i. for each shipment or lot of media, the laboratory has documentation on the media label, package insert, technical manual, or other document, that the manufacturer’s quality control practices conform to specifications; and, ii. the laboratory documents receipt and condition of each shipment or lot of media, and notifies the media manufacturer of: <ul style="list-style-type: none"> - cracked Petri dishes; - unequal filling of plates; - cracked media in plates; - hemolysis; - freezing; - excessive number of bubbles; or - contamination. 	<p>CLSI Approved Standard, Document M22 can be utilized to establish criteria for testing each lot or shipment of commercially prepared media.</p> <p>Copies of CLSI Approved Standard, Document M22 can be obtained from the Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, PA 19087 or www.clsi.org.</p> <p>Users of commercially prepared media should continue to monitor each shipment of media deemed “non-exempt” in the latest version of the CLSI document M22.</p> <p>Media may be tested concurrent with initial use provided QC results are reviewed prior to release of patient results.</p>
<p>Microbiology Sustaining Standard of Practice 3 (MB S3): Media Prepared In-House</p> <p>A sample of each batch of microbiological media prepared in-house shall be tested, prior to or concurrent with initial use, for sterility, ability to support growth, selectivity and/or inhibition, and biochemical responses.</p>	<p>Media may be tested concurrent with initial use provided results are reviewed prior to release of patient results.</p>

Microbiology

Standard	Guidance
<p>Microbiology Sustaining Standard of Practice 4 (MB S4): Expiration Date Prepared In-House</p> <p>The expiration date for each batch of in-house prepared microbiological media shall not exceed 8 weeks from the preparation date for plated and non-screw cap tubed media and six months from the preparation date for screw cap tubed media provided the laboratory:</p> <ul style="list-style-type: none"> a) has taken into account the inclusion of labile components such as antibiotics; b) stores the media under required conditions (e.g. temperature, shielded from light, proper humidity); and, c) has previously tested at least one batch of each medium type and shown it to perform as expected at the end of the designated shelf life. 	<ul style="list-style-type: none"> c) This testing should be repeated when changing vendors.
<p>Microbiology Sustaining Standard of Practice 5 (MB S5): Media for Satellite Locations</p> <p>Laboratories that supply media to satellite locations are responsible for either sending or maintaining quality control documentation and for notification of each satellite location of a recall.</p>	<p>In compliance with Reagents Sustaining Standard 4 (REAG S4), satellite laboratories are responsible for maintaining inventory control documentation which includes the name of the central laboratory provider.</p>
<p>Microbiology Sustaining Standard of Practice 6 (MB S6): Specimen Criteria</p> <p>The SOPM shall define specimen types acceptable for each assay and shall include collection, storage and transport criteria, and rejection criteria.</p>	

Microbiology

Standard	Guidance
<p>Microbiology Sustaining Standard of Practice 7 (MB S7): Automated Identification Systems</p> <p>The laboratory shall check each new lot number or shipment received of reagents with positive and negative reactivity quality control organisms for automated identification systems (QC). A streamlined quality control may be instituted when using microbial automated identification systems (MIS) provided that they follow a written protocol that ensures that they:</p> <ul style="list-style-type: none"> a) performed a verification study; b) maintain documentation that the manufacturer has performed adequate QC to ensure that the system performs appropriately; c) maintain documentation that states that the distributor has followed all the manufacturer’s requirements for shipping and storage; d) store and maintain the system according to the manufacturer’s requirements; e) perform streamlined QC as directed by the manufacturer that integrates the manufacturer’s risk mitigation information ; f) maintain records of all QC performed; g) remediate all QC failures and repeat QC in triplicate before resuming patient testing; and h) notify the manufacturer and distributor of the unresolved QC failure. 	<p>The protocol should be at least as stringent as that outlined in CLSI M50-A.</p> <p>Automated systems used exclusively to screen for bacterial contamination of blood components must also follow this standard. Non-automated screening tests for bacterial contamination of blood components, such as pH or glucose, are covered under the permit category of Blood Services – Transfusion or Blood Services – Collection. Identification of the organism requires a Bacteriology –Comprehensive permit.</p> <ul style="list-style-type: none"> a) A review of historical data may be used for the verification study. <p>Refer to Reagents Sustaining Standard of Practice 2 (REAG S2) and Reagents Sustaining Standard of Practice 3 (REAG S3) for quality control requirements for all other reagents.</p>

Microbiology

Standard	Guidance
<p>Microbiology Sustaining Standard of Practice 8 (MB S8): Laboratory Worksheets</p> <p>Laboratory records shall include worksheets and/or electronic records that include all tests and test results that led to the identification of microorganisms.</p>	<p>Worksheets and/or electronic records should include identification of the media or host systems used and the corresponding observations for each medium as well as biochemical test reactions where appropriate.</p>
<p>Microbiology Sustaining Standard of Practice 9 (MB S9): Reports</p> <p>Reports shall include:</p> <ul style="list-style-type: none"> a) the test methodology; b) an interpretation, when necessary, to explain the significance of the test result; c) a qualifier identifying an assay limitation, if appropriate; and, d) a recommendation for follow-up testing, if appropriate. 	<p>These requirements are in addition to those required by Reporting Sustaining Standard 1 (REP S1).</p> <ul style="list-style-type: none"> a) Examples of assay methodology include culture, EIA, PCR, etc. Specific test systems are not required to be listed on a test report. b) Report qualifiers are used to convey information that would affect the significance and/or clinical interpretation of the test result. c,d) Rapid antigen tests for influenza virus are particularly vulnerable to assay sensitivity issues because of antigenic variations among circulating influenza sub-types/strains and/or the emergence of novel sub-types/strains. The laboratory should be alert to these performance issues and include qualifiers and recommendations for follow-up testing as appropriate.

Microbiology

Standard	Guidance
<p>Microbiology Sustaining Standard of Practice 10 (MB S10): Laboratory Response Network (LRN)</p> <p>The laboratory shall have a section in the SOPM describing policies and practices related to their activities as a Laboratory Response Network (LRN) sentinel (formerly level A) laboratory, if applicable, including:</p> <ul style="list-style-type: none"> a) maintaining updated LRN guidelines and protocols related to the testing, identification and reporting of select and emergent agents including information regarding special handling and safety practices to be employed; b) providing staff with information regarding the biosafety level(s) (BSL) recommended for the microbiological testing being performed and identifying the highest BSL available for each category of microbiological testing; c) identifying the LRN reference laboratory for their facility and contact information for individual(s) to be contacted if a select agent is suspected; and, d) distribution of information to health care providers regarding specimen collection and submission instructions that should be followed when infection with a select agent or other infectious agent requiring special handling is suspected. 	<p>Laboratories holding a clinical laboratory permit in either Bacteriology – Comprehensive or Virology –Comprehensive are currently considered LRN sentinel (formerly Level A) laboratories, unless designated as a LRN reference laboratory.</p> <p>Information regarding laboratory testing for critical and emergent agents is available to all laboratories on the CDC website. LRN sentinel laboratories holding NYS clinical laboratory permits are advised to regularly access the NYSDOH Health Commerce System (HCS) for updated information related to testing, identification and reporting of these agents. Information regarding NYS HCS accounts can be obtained at (866) 325-7743. Laboratories serving NYC should also access the NYC Department of Health and Mental Hygiene’s Health Alert Network (HAN); for information, contact 1-888-NYCMED9 or nycmed@health.nyc.gov.</p> <p>The Wadsworth Center may define the levels of testing (e.g. rule out only) and identification (e.g. presumptive only) and the reporting pathway for a particular agent. The Wadsworth Center’s LRN distributes this information as needed to sentinel laboratories by fax and/or electronic copy to the laboratory director and posts these announcements on the HCS.</p> <p>NYS and NYC LRN reference laboratory contacts and other LRN information is available on the NYSDOH LRN website which is accessed through the HCS. The Wadsworth Center LRN program staff can be contacted at LRNexec@health.state.ny.us.</p> <p>Biosafety levels and associated recommendations and practices are described in the CDC publication “<i>Biosafety in Microbiological and Biomedical Laboratories</i>” (BMBL) and on the CDC website at www.cdc.gov.</p> <p>Laboratories must comply with infectious disease reporting requirements as outlined in the Public Health SS1: Reporting standard.</p> <p>Laboratories must comply with pertinent items of USA Patriot Act and the Select Agent Rule (e.g. disposal/transfer of select rule—see Microbiology Sustaining Standard 11 (MB S11)).</p>

Microbiology

Standard	Guidance
<p>Microbiology Sustaining Standard of Practice 11 (MB S11): Inventory and Track of Select Agents</p> <p>The laboratory shall establish and implement an inventory and tracking system that ensures that all samples and their derivatives suspected or confirmed to contain select agents are accounted for until laboratory findings establish the absence of a select agent. If a select agent is confirmed then documentation of its transfer including record of appropriate packing and shipping or destruction within seven days must be completed.</p>	<p>A list of select agents (Biological Diseases/Agents List) can be found at the federal Centers for Disease Control and Prevention website at http://www.selectagents.gov.</p> <p>Inventory and tracking documentation shall include the identity of all individuals accessing such materials, as well as completion of APHIS/CDC forms 3 (Report of Theft, Loss or Release of Select Agents or Toxins) and 4 (Report of Identification of a Select Agent or Toxin) for organisms and toxins isolated from clinical specimens. This tracking system includes select agents used as control material and for those specimens that are suspected to be positive for a select agent. Tracking will begin at the time it is suspected that a specimen contains a select agent.</p>

Microbiology
Nucleic Acid Amplification (MNA) Assay

Standard	Guidance
<p>Unless otherwise stated these standards apply to FDA-approved assays, modified FDA-approved assays and laboratory developed nucleic acid amplification assays and sequencing assays used for the detection/identification/characterization of infectious agents. Laboratories may not report results obtained using laboratory developed assays or modified FDA-approved assays without prior approval of the assay protocol by the Clinical Laboratory Evaluation Program as per Validation Sustaining Standard of Practice 5 (Validation S5). Application and submission guidelines are available at http://www.wadsworth.org/labcert/TestApproval/index.htm. These standards apply to all microbial agents including HIV and supplement the general systems standards that pertain to molecular test methods.</p>	
<p>The following specialty sustaining standards of practices shall be incorporated into the laboratory's quality management system, where applicable to the scope of services provided. Effective May 1, 2011.</p>	
<p>Microbiology Nucleic Acid Amplification Assays Sustaining Standard of Practice 1 (MNA S1): Employee Training and Competency</p> <p>The laboratory's training and competency program shall:</p> <ul style="list-style-type: none"> a) include practices and procedures that must be implemented in order to reduce the likelihood of cross contamination and other technical errors; b) include direct observation adequate to confirm technical competence in all aspects of each molecular technique; c) require successful testing of a blinded assessment panel that includes samples representative of those expected in the laboratory; d) include documentation that items b and c have been satisfied prior to approving an individual to perform independent testing; and e) include documentation of annual competency assessments for each individual performing molecular assays. 	<p>This standard includes requirements in addition to those stated in Human Resources Sustaining Standard 6 (HR S6) and Human Resources Sustaining Standard 8 (HR S8).</p> <ul style="list-style-type: none"> b,e) A single representative assay may be used to assess competency when using the same methodology, including specimen preparation/extraction, for more than one agent. d,e) Documentation of training should include a direct observation of operator adherence to molecular workflow. <p>Assessment panels may include proficiency test samples or other characterized materials. Sample ranges should be representative of the entire assay range where appropriate however in certain instances it is impractical to obtain high concentrations. A panel should include representative samples with at least one sample at or near the limit of detection.</p> <p>See also Proficiency Test Sustaining Standards and Quality Assessment Sustaining Standard 3 (QA S3).</p>

Microbiology

Nucleic Acid Amplification (MNA) Assay

Standard	Guidance
<p>Microbiology Nucleic Acid Amplification Assays Sustaining Standard of Practice 2 (MNA S2): Prevention and Remediation of Nucleic Acid Contamination</p> <p>The SOPM shall include a description of practices and procedures intended to prevent nucleic acid contamination including:</p> <ul style="list-style-type: none"> a) a workflow pattern that utilizes separate areas and moves unidirectionally from pre- to post-amplification processes; b) dedicated pre-amplification equipment, reagents, supplies, and PPE that have been neither stored nor used in post-amplification areas or other areas that may result in exposure to amplicon, plasmids, and culture-amplified materials; c) the handling, processing and storing of clinical specimens and pre-amplification reagents and supplies (e.g. extraction reagents, mastermix, probes) in a manner that prevents exposure to amplicon; d) a decontamination and remediation plan to be implemented in the event that amplicon contamination is identified. 	<p>Item a of this standard does not apply to FDA approved Closed System Amplification Tests (CSATs).</p> <p>Pre-amplification activities include the storage, processing and extraction of clinical specimens and preparation of assay reagents. Post-amplification activities include those processes that occur after molecular amplification has been performed and result in an exponential increase in the amount of nucleic acid product (amplicon).</p> <ul style="list-style-type: none"> a) The unidirectional workflow pattern is intended to ensure that pre-amplification procedures are performed in a work area that excludes amplification products (amplicon). The high level of concern is based on the significant risk of generating false-positive test results due to amplicon contamination of patient specimens and/or pre-amplification supplies and reagents. Failure to adhere to the established unidirectional workflow pattern requires implementation and documentation of additional measures for monitoring and preventing amplicon contamination. These measures may include the use of UNG in PCR assays, use of amplicon contamination monitoring programs such as swipe testing of molecular areas, and the use of decontamination products designed to eliminate nucleic acid contaminants. a) The practices and space designation policies should be tailored to the laboratory's test menu and design. Ideally, a laboratory should have 3 separate rooms for performing nucleic acid amplification assays: a pre-amplification reagent preparation room; a room used for specimen preparation/nucleic acid extraction and for template addition; and, a room dedicated to post-amplification processes. An alternative arrangement may be developed within a room where reagent preparation (e.g. mastermix set-up and template addition) are performed in distinct areas provided that strictly dedicated and delineated areas, PCR workstations, supplies, reagents, etc. are utilized for separating the two pre-amplification phases of work. However, it remains a high priority that post-amplification procedures be performed in a separate room. a) It is suggested that negative controls in addition to those required when performing FDA approved assays be included when "open amplicon" systems are utilized in a laboratory that does not have at least two separate <u>rooms</u> for pre- and post-amplification activities. a) Individuals performing CSATs may return to pre-amplification areas since the closed systems do not release amplicon into the environment provided that assay and discard procedures are followed.

Microbiology

Nucleic Acid Amplification (MNA) Assay

Standard	Guidance
<p>Microbiology Nucleic Acid Amplification Assays Sustaining Standard of Practice 2 (MNA S2): Prevention and Remediation of Nucleic Acid Contamination - continued</p>	<ul style="list-style-type: none"> b) This refers to all equipment, furniture, instruments, supplies, reagents and PPE, including, but not limited to, pipets, pipettors, bulbs, tips, pens, discard containers, and clerical and cleaning supplies. PPE includes all laboratory coats/smocks, booties, hair bonnets, gloves, safety glasses and other individually-worn barriers. Worksheets and manuals that have been in post-amplification areas must not be brought into pre-amplification areas. b) Plugged (aerosol barrier) tips or positive displacement pipets are recommended for pre-amplification procedures. c) Ideally, a room under positive pressure relative to the post-amplification room should be used for preparation of mastermix and other “clean” reagents. d) The remediation plan should: define the decontamination procedure(s) to be employed; include root cause investigation, corrective action, competency assessment with retraining if necessary, and evidence supporting the adequacy of the remediation/decontamination procedures (e.g. environmental monitoring, increasing the number of negative controls per run).
<p>Microbiology Nucleic Acid Amplification Assays Sustaining Standard of Practice 3 (MNA S3): Instrumentation</p> <p>The laboratory shall:</p> <ul style="list-style-type: none"> a) operate instruments and run internal performance checks according to the manufacturer’s instructions and/or the laboratory’s validated procedures; and, b) verify the uniformity of temperature across all sample chambers at inception, annually, and after servicing. 	<ul style="list-style-type: none"> a) Instruments include all instruments used for nucleic acid testing such as thermal cyclers, real time PCR instruments, optical instruments, heat blocks, automated extraction systems, and sequencing instrumentation. b) Documentation of manufacturer verification is acceptable. Verification should include monitoring of temperature ramping rates where applicable. This may be met by using a verified low positive control in every well or an electronic check for temperature homogeneity. b) Cross platform verification can be performed by monitoring positive controls utilized in each instrument run.

Microbiology

Nucleic Acid Amplification (MNA) Assay

Standard	Guidance
<p>Microbiology Nucleic Acid Amplification Sustaining Standard of Practice 4 (MNA S4): Reagent Storage</p> <p>Probes, primers and other labile reagents used in nucleic acid amplification assays shall be stored and maintained in accordance with manufacturer's instructions. In the absence of these, the laboratory's own validation data shall be used to establish acceptable storage and maintenance parameters.</p>	<p>Probes, primers and mastermix should be stored in small aliquots to minimize the number of freeze-thaw cycles. An acceptable number of freeze-thaw cycles may be stated by the manufacturer or established by monitoring control results that are appropriate (e.g. low level analyte) for identifying reagent deterioration.</p> <p>Bulk mastermix storage and preparation criteria should be validated by the laboratory to ensure the integrity of the reagent over the designated shelf life interval. Expiration dates for these reagents shall be based on laboratory validation studies where appropriate.</p>

Microbiology

Nucleic Acid Amplification (MNA) Assay

Standard	Guidance
<p>Microbiology Nucleic Acid Amplification Assay Sustaining Standard of Practice 5 (MNA S5): Quality Control Samples for Laboratory Developed and Modified FDA-approved MNAs</p> <p>Each assay protocol for all laboratory developed MNA assays and modified FDA approved assays shall define the acceptable detection range for all controls and each run shall include at least:</p> <ul style="list-style-type: none"> a) one control capable of detecting amplification inhibition by patient specimens unless the CLRS-approved application/method exempts the requirement; b) for qualitative assays, a negative control and a low range positive control that assess the entire assay, including specimen preparation/extraction (except for sequence based assays); c) for quantitative assays, a negative control and at least 2 positive controls that assess a reasonable portion of the linear range of the assay including specimen preparation/extraction; and, d) additional negative controls in laboratories that manipulate amplicon but do not use separate rooms for pre- and post-amplification processes. 	<p>This standard applies to controls to be used with laboratory developed assays and FDA-approved assays that have been modified by the laboratory. Controls for unmodified FDA-approved assays should minimally include those recommended by the manufacturer and those that meet the requirements of other applicable standards.</p> <p>Negative controls including template-free mastermix controls not only serve to identify technical and/or reagent issues but also help identify amplicon contamination. The negative controls may include a reagent processing control that serves as both a template-free mastermix reagent control as well as a processing/extraction negative control.</p> <p>For laboratories preparing mastermix to be used on multiple instruments, the template-free mastermix control should be utilized for each run of each instrument.</p> <ul style="list-style-type: none"> a) Inhibition controls may be excluded if there are sufficient data showing that the inhibition rate is less than 1% for a specimen type for the assay. It is possible to extend inhibition data to other analytes when applying the same extraction procedure and specimen matrix and utilizing the same amplification methodology. a) Inhibition controls are not required if the run includes isolates only and not patient specimens. b,c) A low-range positive is defined as having a value of not more than 10-fold above the assay detection limit. b,c) For multiplex assays, a low range control is required for each target. These may be run on a rotating basis and may include pools of 3-4 targets. d) Processes that involve manipulation of amplicon include conventional PCR and nucleic acid sequencing. d) It is recommended that the number of negative controls equal at least 2% of the patient specimen test number and that these are interspersed randomly throughout patient specimens (e.g. 2 per 96-well plate). <p>Note: Refer to the Application for Approval of Infectious Agent Nucleic Acid Amplification Tests (http://www.wadsworth.org/labcert/TestApproval/index.htm) for additional guidance related to assay control ranges or exemptions from use of inhibition controls.</p>

Microbiology

Nucleic Acid Amplification (MNA) Assay

Standard	Guidance
<p>Microbiology Nucleic Acid Amplification Assay Sustaining Standard of Practice 6 (MNA S6): Quality Control Samples for Sequencing Assays</p> <p>Each sequencing assay shall include a</p> <ul style="list-style-type: none"> a) negative amplification control; b) negative sequencing control; c) positive sequencing control; and d) positive amplification and inhibition controls when testing primary specimens using laboratory developed assays or modified FDA approved assays. 	<p>Laboratories using a core facility do not need to provide negative and positive sequencing amplification controls if the assay performed by the core facility includes negative and positive sequencing controls.</p> <ul style="list-style-type: none"> a,b) The negative amplification control may also be used as the negative sequencing control. a) Purified plasmid that is supplied with a commercially available kit may be used as a positive sequencing control. Previously tested and well characterized PCR product of the target from clinical samples can also be used as sequencing controls. d) Positive amplification controls and inhibition controls are not necessary when performing sequencing on clinical isolates. d) Positive amplification and inhibition controls may be omitted when testing primary specimens for genotyping assays for prognostic purposes. If there is no amplification product or genotype resulting from a primary specimen, the report must document that the result may be due to the following: virus was below the limit of detection in the sample, mutations were present in the virus genome, or inhibitors were present in the sample that prevented amplification. <p>Note: Refer to the Application for Approval of Infectious Agent Nucleic Acid Amplification Tests (http://www.wadsworth.org/labcert/TestApproval/index.htm) for further information.</p>

Microbiology Nucleic Acid Amplification (MNA) Assay

Standard	Guidance
<p>Microbiology Nucleic Acid Amplification Assay Sustaining Standard of Practice 7 (MNA S7): Reports for Laboratory Developed and Modified FDA Approved Sequence-based Assays</p> <p>Reports shall describe the relationship between the observed result and the predicted phenotype.</p>	<p>This standard does not apply to sequence-based assays for identification.</p> <p>For unmodified FDA -approved assays reporting should be consistent with the manufacturer’s instructions.</p> <p>Reports containing test results generated using sequencing, probe-based, and other genotype assays should include information stating the relationship between the observed result(s) and the related characteristic such as prediction of drug resistance or virulence.</p> <p>Mutations should not be reported as indicative of drug resistance or virulence unless there is well-supported documentation in peer-reviewed literature.</p> <p>Refer to the Application for Approval of Infectious Agent Nucleic Acid Amplification Tests available at http://www.wadsworth.org/labcert/TestApproval/index.htm for additional requirements.</p>
<p>Microbiology Nucleic Acid Amplification Assay Sustaining Standard of Practice 8 (MNA S8): Task Separation for FDA-Approved Closed System Amplification Test (CSATS)</p> <p>The laboratory shall:</p> <ol style="list-style-type: none"> a) Handle, process, and store clinical specimens, reagents and supplies in a manner that prevents exposure to amplicon, plasmids, and culture-amplified materials; and b) Locate the instrument in an area free of open amplicon systems. 	<p>A CSAT refers to an assay in which all steps, including post-amplification steps, are performed and contained within a closed system. A closed system is defined as an instrument in which the patient specimen is directly added to the test unit, device, or cartridge, sealed, and then the testing process is initiated with no additional external manipulation or addition of reagents (either manually or robotically).</p> <p>CSAT instrumentation should be segregated from areas in which specimens are routinely processed in order to avoid cross-contamination.</p> <p>An individual performing CSAT may return to pre-amplification areas since the closed systems do not release amplicon into the environment provided that assay and discard procedures are followed.</p>

Microbiology

Nucleic Acid Amplification (MNA) Assay

Standard	Guidance
<p>Microbiology Nucleic Acid Amplification Assay Sustaining Standard of Practice 9 (MNA S9): Controls for FDA-Approved Closed System Amplification Tests (CSATs)</p> <p>Positive target controls and negative controls that assess the entire assay shall be run on each new lot number or shipment prior to reporting patient results and on each day of use for FDA-Cleared Closed System Amplification tests (CSATs) unless the laboratory has validated a reduced quality control schedule that minimally includes a:</p> <ul style="list-style-type: none">a) positive target control run at least monthly;b) negative control run at least weekly.	<p>The validation studies should demonstrate acceptable quality control results at the interval corresponding to the laboratory's quality control schedule. The laboratory is not required to run quality control every day in the time period to verify reagent stability.</p>

Microbiology Bacteriology

Standard	Guidance
<p>The following specialty sustaining standards of practices shall be incorporated into the laboratory's quality management system, where applicable to the scope of services provided.</p> <p>The laboratory must also follow the Microbiology and Molecular Microbiology Standards. Effective May 1, 2011.</p>	<p>Reference: Clinical Microbiology Procedures Handbook, Second Edition Update, 2007.</p>
<p>Bacteriology Standard of Practice 1 (BT S1): Reagent QC</p> <p>The laboratory shall check positive and negative reactivity with control organisms as follows:</p> <ul style="list-style-type: none"> a) each day of use for beta-lactamase and all stains other than Gram stain; b) each week of use for Gram stain; c) every 6 months for antisera. 	<ul style="list-style-type: none"> c) Polyvalent antisera should be tested with at least one organism from each polyvalent group.
<p>Bacteriology Standard of Practice 2 (BT S2): Urine Loops</p> <p>Non-disposable urine loops shall be calibrated monthly.</p>	<p>Calibration may be performed using a blue-dye methodology or by using a calibrated drill bit.</p>
<p>Bacteriology Standard of Practice 3 (BT S3): Anaerobic Containers</p> <p>The environmental conditions of anaerobic bags, jars, and glove boxes shall be monitored and documented each day of use.</p>	<p>An oxygen sensitive indicator such as methylene blue, resazurine, or a control culture of <i>Clostridium novyi B</i> should be placed in anaerobic jars or chambers to ensure anaerobic conditions are met.</p>

Microbiology Bacteriology

Standard	Guidance
<p>Bacteriology Standard of Practice 4 (BT S4): Aerobic Blood Cultures</p> <p>Macroscopically negative aerobic blood cultures shall be subcultured at some point before discarding.</p>	<p>Subcultures need not be done on blood cultures performed by radiometric methods or automated non-radiometric methods if the bottles are monitored for five days.</p>
ANTIMICROBIAL SUSCEPTIBILITY TESTING: DISK DIFFUSION AND MINIMAL INHIBITORY CONCENTRATION	
<p>Bacteriology Standard 5 (BT S5): Defining Antibiotic Panels</p> <p>Antibiotic panels appropriate to the specimen source and organism isolated shall be defined.</p>	<p>Guidelines should be established for the number and type of antibiotics tested and/or reported for organisms isolated from different sources. It is recommended that, in a hospital setting, the laboratory periodically reviews the most current formulary established by the pharmacy and/or the Infection Control Committee.</p>
<p>Disk diffusion methods (Standards 6-9)</p>	<p>It is recommended that laboratories performing disk diffusion testing have access to the latest CLSI guidelines (M02) and performance standards (M100).</p>
<p>Bacteriology Standard of Practice 6 (BT S6): Media QC for Disk Diffusion Methods</p> <p>Each batch of media used for antimicrobial susceptibility testing shall be checked with the appropriate control strains before, or concurrent with, initial use utilizing approved reference organisms.</p>	<p>If performed concurrently with patient testing, QC results should be reviewed prior to release of patient results.</p>
<p>Bacteriology Standard of Practice 7 (BT S7): Antibiotic QC for Disk Diffusion Methods</p> <p>Using known reference organisms, the laboratory shall check each new lot of antimicrobial disks before, or concurrent with, initial use.</p>	<p>If performed concurrently with patient testing, QC results should be reviewed prior to release of patient results.</p>

Microbiology Bacteriology

Standard	Guidance
<p>Bacteriology Standard of Practice 8 (BT S8): Antibiotic Disk Distribution</p> <p>Antibiotic disks shall be evenly distributed over the culture plate not less than 15 mm from the outer edge of the plate and no closer than 24 mm from center to center except when specifically directed otherwise by the manufacturer’s directions or generally accepted standards of practice.</p>	<p>Generally, no more than 12 disks should be distributed on a 150 mm petri plate and no more than 5 disks on a 100 mm plate. For <i>Haemophilus</i> species, <i>Neisseria gonorrhoeae</i>, and <i>Streptococcus</i> species (including <i>Streptococcus pneumoniae</i>), no more than 9 disks per 150 mm plate and no more than 4 disks per 100 mm plate should be used.</p>
<p>Bacteriology Standard of Practice 9 (BT S9): Disk Diffusion QC Frequency, Assessment and Recording</p> <p>For antimicrobial susceptibility disk diffusion testing, the laboratory shall:</p> <ul style="list-style-type: none"> a) use the appropriate control organism(s) to check the procedure each day of testing; or b) test each appropriate control strain a minimum of once each week during which patients are tested, provided the laboratory has demonstrated satisfactory performance of quality control testing by testing control strains each day of use for at least 20 days; c) record zone sizes for each antimicrobial quality control test; and d) establish accuracy control limits. 	<ul style="list-style-type: none"> c) Zone sizes may be measured using a ruler, sliding calipers, templates, or other appropriate measurement devices prepared for this purpose. d) The accuracy control limit is the acceptable range of zone diameters for that drug-microorganism combination used for quality control. <p>The laboratory may establish accuracy control limits or the laboratory may use the accuracy control limits provided in the current CLSI Approved Standards, Performance Standards for Antimicrobial Susceptibility Testing.</p>

Microbiology Bacteriology

Standard	Guidance
<p>Minimal inhibitory concentration methods (MIC) (standards 10-11)</p>	<p>It is recommended that laboratories performing MIC testing have access to the latest CLSI guidelines (M07) and performance standards (M100).</p>
<p>Bacteriology Standard of Practice 10 (BT S10): Reagent QC for MIC methods</p> <p>Each batch of macrodilution tubes, microdilution plates, concentration strips, and agar dilution plates used for MIC antimicrobial susceptibility testing shall be checked with the appropriate control strains before, or concurrent with, initial use using approved reference organisms.</p>	<p>If performed concurrently with patient testing, QC results should be reviewed prior to release of patient results.</p>
<p>Bacteriology Standard of Practice 11 (BT S11): MIC Quality Control Frequency, Assessment and Recording</p> <p>For MIC antimicrobial susceptibility testing, the laboratory shall:</p> <ul style="list-style-type: none"> a) use the appropriate control organism(s) to check the procedure each day of testing; or b) test each appropriate control strain a minimum of once each week during which patients are tested, provided the laboratory has demonstrated satisfactory performance of quality control testing or by satisfactory testing of control strains each day of use for at least 20 days; c) record the actual MIC obtained during QC testing; and d) establish accuracy quality control limits. 	<ul style="list-style-type: none"> a) Consult CLSI documents for appropriate quality control strains and acceptable guidelines for weekly QC testing. d) The accuracy control limit is the acceptable range for that drug-microorganism combination used for quality control. <p>The laboratory may establish accuracy control limits or the laboratory may use the accuracy control limits provided in the current CLSI Approved Standards, Performance Standards for Antimicrobial Susceptibility Testing.</p>

Microbiology Mycobacteriology	
Standard	Guidance
<p>The following specialty sustaining standards of practices shall be incorporated into the laboratory's quality management system, where applicable to the scope of services provided.</p>	
ALL CATEGORIES	
<p>Mycobacteriology Standard 1 (TB S1)</p> <p>For mycobacteriological staining, a positive and negative control shall be run with each new shipment or lot of stain and:</p> <ul style="list-style-type: none"> a) for fluorochrome stains, each time of use; and, b) for stains other than fluorochrome, each day of use. 	
<p>Mycobacteriology Standard 2 (TB S2)</p> <p>To minimize the possibility of specimen cross-contamination, slides shall be stained individually.</p>	<p>Batch staining with jars or dishes is not permitted.</p>
<p>Mycobacteriology Standard 3 (TB S3)</p> <p>Each shipment or lot of commercial test system or test reagent(s) shall be tested with:</p> <ul style="list-style-type: none"> a) at least one organism which produces the expected biochemical reaction (positive control); and, b) one organism which shows that the expected biochemical reaction does not occur (negative control). 	<ul style="list-style-type: none"> a) During the decontamination of patient specimens, the positive control should be removed from the batch. False positive results have been reported due to contamination with a control that contained a high concentration of organisms (i.e. TB or NTM culture).

Microbiology
Mycobacteriology

Standard	Guidance
<p>Mycobacteriology Standard 4 (TB S4)</p> <p>Acid-fast stain results, both positive and negative, shall be reported to the ordering physician or other authorized person within 24 hours of the receipt of the specimen.</p>	<p>Reporting time should be periodically monitored to ensure compliance.</p>
<p>Mycobacteriology Standard 5 (TB S5)</p> <p>The laboratory shall have documentation that positive fluorochrome stains in newly diagnosed patients:</p> <p>a) are confirmed by carbol fuchsin stain; or, b) are independently interpreted as positive by a second qualified person.</p>	
<p>Mycobacteriology Standard 6 (TB S6)</p> <p>Negative acid-fast stained slides shall be retained until the final culture report has been issued.</p>	<p>The laboratory should implement a quality assurance monitor to assess proficiency with microscopy. This might include an independent review of a percentage (as determined by the laboratory director) of negative slides, or as a minimum, review of all smears from smear-negative, culture-positive specimens.</p>
<p>Mycobacteriology Standard 7 (TB S7)</p> <p>Positive acid-fast stained slides shall be retained for one year.</p>	<p>Fluorochrome slides will fade with time, so they should be retained in the dark. The slides may be retained with a carbol-fuchsin method if necessary.</p>

Microbiology **Mycobacteriology**

Standard	Guidance
<p>Mycobacteriology Standard 8 (TB S8)</p> <p>All respiratory specimens which test acid-fast smear positive and are from patients who have not previously been diagnosed with tuberculosis shall have nucleic acid amplification testing performed.</p>	<p>Specimens from patients with a past history of NTM infection and without clinical suspicion of tuberculosis (e.g., cystic fibrosis patients) do not need nucleic acid amplification testing performed.</p> <p>If the laboratory does not have the capability to perform nucleic acid amplification testing, an additional respiratory specimen shall be immediately requested and sent to a NYS-permitted laboratory that performs nucleic acid amplification.</p>
<p>Mycobacteriology Standard 9 (TB S9)</p> <p>For initial smear and culture positive respiratory specimens, the time elapsed between the date the specimen is taken and the date the susceptibility testing results for rifampin are reported shall be less than four weeks for 80% of these specimens.</p>	<p>This applies only to isolates identified or suspected of being <i>Mycobacterium tuberculosis</i> complex.</p> <p>This should be an ongoing quality assurance monitor.</p>
SMEARS ONLY	
<p>Mycobacteriology Standard 10 (TB S10)</p> <p>Due to limited sensitivity, microscopy reports shall indicate that:</p> <p>a) the smear result shall be used as an adjunct in evaluating a patient's tuberculosis status; and, b) cultural examination is highly recommended for laboratory diagnosis.</p>	
COMPREHENSIVE, RESTRICTED	
<p>Mycobacteriology Standard 11 (TB S11)</p> <p>A biological safety cabinet (BSC) shall be used.</p>	<p>Refer to Safety Sustaining Standard of Practice 6 (SAF S6) for operational guidelines.</p>

Microbiology Mycobacteriology

Standard	Guidance
<p>Mycobacteriology Standard 12 (TB S12)</p> <p>For all mycobacteriology procedures that use centrifuges:</p> <ul style="list-style-type: none"> a) aerosol-free centrifuge cups shall be used; and, b) specimens shall be spun for a minimum of 15 min at greater than or equal to 3000 x g. 	
<p>Mycobacteriology Standard 13 (TB S13)</p> <p>When performing patient testing, laboratories shall label initial and subsequent testing materials with:</p> <ul style="list-style-type: none"> a) the specimen's accession number; b) the last name or other personal identifier that is not numerical; and c) the date of implementation of each phase of testing. 	<p>Errors have been attributed to mislabeling or misidentifying specimen material through the testing process.</p> <ul style="list-style-type: none"> b) Since numbers can be easily transposed/misread, the use of the patient's last name may prevent errors in identification. c) The date of implementation may be the date that labels are generated. In the case of a small vial and the test is completed the same day and the date is captured on a work sheet, the name and the accession number may be sufficient.
<p>Mycobacteriology Standard 14 (TB S14)</p> <p>At least one solid and one liquid medium shall be inoculated for culturing AFB (except for blood specimens processed with the BACTEC system using 13A bottles or Myco/F Lytic medium).</p>	<p>Solid media might include, but are not limited to: Lowenstein-Jensen, Lowenstein-Jensen Gruft, Lowenstein-Jensen with Iron, Lowenstein-Jensen with Pyruvic Acid, Middlebrook 7H10, Selective Middlebrook 7H10, Middlebrook 7H11, and Selective Middlebrook 7H11.</p> <p>Liquid media might include, but are not limited to, BACTEC™ 12B, Septi-Chek™ AFB, BACTEC™ MGIT™, ESP® Myco, MB/BacT®, BACTEC™ 9000MB.</p> <p>If a laboratory is using Septi-Chek™ with the paddle, an additional solid medium should be used.</p>

Microbiology **Mycobacteriology**

Standard	Guidance
<p>Mycobacteriology Standard 15 (TB S15)</p> <p>The purity of a positive acid-fast culture in liquid media shall be verified.</p>	
<p>Mycobacteriology Standard 16 (TB S16)</p> <p>If susceptibility cannot be performed in-house, the culture should be referred in 24 hours to a New York State permitted laboratory for testing.</p>	<p>The laboratory that recovers initial <i>M. tuberculosis</i> complex isolates is responsible for assuring that susceptibility testing is performed.</p> <p>Whenever possible, the primary isolation media (i.e., 3-ml broth aliquot or slant) should be immediately submitted and a subculture should be retained in the originating laboratory.</p> <p>The laboratory should periodically monitor the time period from initial identification to the receipt of culture by the reference laboratory in order to assess the adequacy of isolate transport/shipping.</p>
<p>Mycobacteriology Standard 17 (TB S17)</p> <p>All initial isolates of <i>M. tuberculosis</i> complex shall be submitted to either the Wadsworth Center or NYC Public Health Laboratories, as appropriate, for DNA typing within 24 hours of a positive test result for <i>M. tuberculosis</i> complex. All other isolates must be saved for 12 months.</p>	<p>Laboratories located within New York City submit isolates to the NYC Public Health Laboratories; laboratories outside of New York City (upstate and out-of-state) submit isolates to the Wadsworth Center in Albany, NY.</p> <p>For all laboratories, <i>M. tuberculosis</i> complex isolated by the New York State Fast-Track Program do not need to be resubmitted to either public health laboratory by the original submitter. Isolates may be retained on appropriate media and stored at 4-8 degrees Celsius or may be frozen at -70 degrees Celsius to -80 degrees Celsius.</p> <p>To expedite the genotyping testing, an aliquot of at least 3ml of the primary broth medium is recommended rather than waiting for a mature subculture on a slant.</p>

Microbiology Mycobacteriology

Standard	Guidance
<p>Mycobacteriology Standard 18 (TB S18)</p> <p>The laboratory shall identify <i>M. avium</i> complex or <i>M. gordonae</i> by use of AFB morphology and genetic probe.</p>	<p>Identification of these two taxons by use of biochemical reactions is not satisfactory.</p>
COMPREHENSIVE	
<p>Mycobacteriology Standard 19 (TB S19)</p> <p>Laboratories performing susceptibility testing of <i>M. tuberculosis</i> complex for first-line tuberculosis drugs shall identify <i>M. tuberculosis</i> and are responsible for ensuring a final identification in the event of <i>M. tuberculosis</i> complex- not <i>M. tuberculosis</i> isolate.</p>	<p>This requirement can be met by in-house testing under the appropriate subcategory or by referral of the specimen to an appropriate NYS-permitted laboratory.</p> <p>All <i>M. tuberculosis</i> complex- not <i>M. tuberculosis</i> isolates shall be referred to Wadsworth Center for final identification.</p> <p>Only <i>M. tuberculosis</i> identification should be performed in a laboratory holding a Mycobacteriology – Restricted permit.</p>
<p>Mycobacteriology Standard 20 (TB S20)</p> <p>A commercial liquid-based test system shall be used for <u>indirect</u> susceptibility testing.</p>	<p><u>Direct</u> susceptibility testing is not recommended when using liquid-based test systems for first- and second-line drugs.</p>
<p>Mycobacteriology Standard 21 (TB S21)</p> <p>For susceptibility tests performed on <i>M. tuberculosis</i> complex isolates, the laboratory shall include a fully susceptible strain of <i>M. tuberculosis</i> at least once per week of use.</p>	<p>The laboratory can determine the MIC of each drug tested in order to quickly recognize problems with the test system.</p>

Microbiology Mycobacteriology

Standard	Guidance
<p>Mycobacteriology Standard 22 (TB S22)</p> <p>All initial isolates of <i>M. tuberculosis</i> complex shall be tested against the following first-line tuberculosis drugs:</p> <ul style="list-style-type: none"> - Rifampin (RMP) - Isoniazid (INH) - Pyrazinamide (PZA) - Ethambutol (EMB) - Streptomycin (SM) 	
<p>Mycobacteriology Standard 23 (TB S23)</p> <p>If the laboratory does not have the capability to perform PZA susceptibility testing, the isolate shall be immediately sent to a New York State permitted laboratory that performs PZA testing.</p>	<p>The laboratory should periodically monitor the time period from initial identification to the receipt of culture by the reference laboratory in order to assess the adequacy of isolate transport/shipping.</p>
<p>Mycobacteriology Standard 24 (TB S24)</p> <p>For all initial isolates of <i>M. tuberculosis</i> complex, if resistance is found to one or more first-line drugs, additional susceptibility shall be performed using second-line drugs with the exception of mono-PZA resistance.</p>	<p>If second-line drug susceptibility cannot be performed in-house, the culture should be immediately referred to a New York State permitted laboratory for testing. Whenever possible, the primary isolation media (i.e., 3-ml broth aliquot or slant) should be immediately submitted and a subculture should be retained in the originating laboratory.</p> <p>Initial test results should not be held pending the additional testing, and should be reported immediately noting the additional testing being performed</p> <p>The laboratory should periodically monitor the time period from reporting first-line drugs to the receipt of culture by the reference laboratory in order to assess the adequacy of means of isolate transport/shipping.</p>

Microbiology Mycobacteriology

Standard	Guidance
<p>Mycobacteriology Standard 25 (TB S25)</p> <p>Susceptibility results for all initial isolates of <i>M. tuberculosis</i> complex showing resistance to one or more first-line drugs and for all isolates that change drug susceptibility patterns shall be confirmed at the NYC Public Health Laboratories or at the Wadsworth Center, as appropriate.</p> <p>While performing confirmatory testing, all first line drugs shall be repeated in addition to second-line drug testing.</p>	<p>Initial test results should not be held pending the additional testing, and should be reported immediately noting the additional testing being performed.</p> <p>Laboratories located within New York City submit isolates to the NYC Public Health Laboratories; laboratories outside of New York City (upstate and out-of-state) submit isolates to the Wadsworth Center in Albany, NY. The laboratory should maintain records of confirmation studies.</p>
<p>Mycobacteriology Standard 26 (TB S26)</p> <p>For antimycobacterial susceptibility tests, the laboratory must check each batch of media and each lot number and shipment of antimycobacterial agent(s) before, or concurrent with, initial use, using an appropriate control organism(s).</p> <p>a) the laboratory must establish limits for acceptable control results; b) each week tests are performed, the laboratory must use the appropriate control organism(s) to check the procedure; c) the results for the control organism(s) must be within established limits before reporting patient results; and d) the laboratory must document all control procedures performed.</p>	

Microbiology Mycology

Standard	Guidance
<p>The following specialty sustaining standards of practices shall be incorporated into the laboratory's quality management system, where applicable to the scope of services provided.</p>	
<p>Mycology Standard 1 (MY S1)</p> <p>A biological safety cabinet (BSC) shall be used for processing specimens.</p>	<p>The use of at least a Class II BSC is recommended.</p> <p>Refer to Safety Sustaining Standard of Practice 6 (SAF S6) for operational guidelines.</p>
<p>Mycology Standard 2 (MY S2)</p> <p>For all mycology procedures that require centrifugation, aerosol-free centrifuge cups shall be used.</p>	
<p>Mycology Standard 3 (MY S3)</p> <p>The mycology laboratory shall have a 30 degrees Celsius incubator and other incubators needed to maintain temperatures for the isolation and growth of pathogenic fungi.</p>	<p>If cultures are incubated at room temperature (22-26 degrees Celsius), the temperature should be documented each day of testing to ensure that proper growth conditions are maintained.</p>

Microbiology Mycology

Standard	Guidance
<p>Mycology Standard 4 (MY S4)</p> <p>Laboratories shall maintain media for:</p> <ul style="list-style-type: none"> a) the isolation of antibiotic-sensitive zoopathogenic fungi; b) the initial isolation of cycloheximide-sensitive fungal pathogens and the elimination of bacterial contamination; and, c) the initial isolation of fungal pathogens and elimination of bacterial and fungal contaminants; 	<p>Examples of suitable media are as follows (Note: The listed examples are not all-inclusive):</p> <ul style="list-style-type: none"> a) Sabouraud dextrose agar - no antibacterial or antifungal agents; b) Sabouraud dextrose agar - with antibacterial agents, or inhibitory mold agar; c) Sabouraud dextrose agar - with antibacterial and antifungal agents (e.g., Mycosel);
<p>Mycology Standard 5 (MY S5)</p> <p>Laboratories shall maintain:</p> <ul style="list-style-type: none"> a) a medium for the assessment of morphologic features of yeast-like pathogens; and, b) a commercial diagnostic system for the identification of yeast-like pathogens. 	<ul style="list-style-type: none"> a) Cornmeal or cream of rice medium with Tween® 80; b) Commercial yeast identification kit, either carbohydrate assimilation or enzyme-based (e.g., API® 20C AUX, Baxter MicroScan, Vitek®).
<p>Mycology Standard 6 (MY S6)</p> <p>Laboratories with a Mycology General permit shall maintain a diagnostic medium to stimulate conidial formation required in the identification of zoopathogenic molds.</p>	<p>Examples of suitable media and stains are as follows (Note: The listed examples are not all-inclusive):</p> <p>Malt extract agar, potato dextrose agar, potato flake agar, or cornmeal.</p>

Microbiology Mycology

Standard	Guidance
<p>Mycology Standard 7 (MY S7)</p> <p>Primary clinical specimens and primary isolates of molds and yeasts shall be examined by direct microscopy using an appropriate mounting medium or stain.</p>	<p>Based upon clinical history and nature of the primary specimen, a direct examination is required with one of the following reagents or stains: potassium hydroxide, India ink, or Cellufluor mounts, or Gram, Giemsa or Methenamine silver stain, or other appropriate methods.</p> <p>Primary isolates may be examined with Lactophenol cotton blue, Cellufluor, India ink, Giemsa stain, or other appropriate methods.</p>
<p>Mycology Standard 8 (MY S8)</p> <p>The laboratory shall check positive and negative reactivity with control organisms as follows:</p> <ul style="list-style-type: none"> a) each day of use for DNA probes; and fluorescent antibody stains; b) each week of use for all other stains; all reagents used with biochemical tests and other test procedures for mycological identification; c) as recommended by the manufacturer of manual, automated, or semi-automated identification systems but not less frequently than with each new lot or shipment received; d) for lactophenol cotton blue each batch when prepared in-house, each lot when commercially prepared and each shipment. 	<ul style="list-style-type: none"> b) Reagents and test procedures used for identification purposes (including, but not limited to, germ tube, yeast and mold morphology media) should be tested with an organism that produces a positive reaction. c) Includes commercial yeast identification kits. See Microbiology Sustaining Standard 2 (MB S2) guidance.
ANTIFUNGAL TESTING: YEAST ONLY	
<p>Laboratories performing this testing should follow Mycology Standards 1 and 2 in addition to the applicable standards outlined below:</p>	

Microbiology Mycology

Standard	Guidance
<p>Mycology Standard 9 (MY S9)</p> <p>For susceptibility testing, laboratories shall only report results for those drugs where published standards for interpreting results exist, or where ranges have been established by the laboratory and approved by the department.</p>	<p>Guidelines for selection of appropriate drugs to be tested against pathogenic yeast are provided in Rex, et. al. (Clinical Microbiology Reviews, October, 2001 and other recent publications). NCCLS document provides guidelines for the following drugs:</p> <p style="padding-left: 40px;">Amphotericin B Fluconazole Flucytosine Itraconazole Ketoconazole</p> <p>Additional drugs, including recently approved entities such as caspofungin, voriconazole, etc., can be tested by providing validation data to the department for review and approval before commencing patient testing. Similarly, newly described testing methods can be adapted for antifungal susceptibility testing by proper validation of test results.</p>
<p>Mycology Standard 10 (MY S10)</p> <p>Reports for yeast susceptibility testing shall include a statement on the limitations and reliability of the interpretative guidelines.</p>	<p>The limitations should indicate the basis for establishing susceptibility ranges such as specific diseases, animal models and the reliability of break points. Protocols based on the NCCLS M27-A method, including commercial products, should use the interpretative guidelines in that document.</p>
<p>Mycology Standard 11 (MY S11)</p> <p>Laboratories shall maintain an incubator at 35° C for susceptibility testing.</p>	

Microbiology Mycology

Standard	Guidance
<p>Mycology Standard 12 (MY S12)</p> <p>For antifungal susceptibility tests, the laboratory must check each batch of media and each lot number and shipment of antifungal agent(s) before, or concurrent with, initial use, using an appropriate control organism(s).</p> <p>a) The laboratory must establish limits for acceptable control results. b) Each day tests are performed, the laboratory must use the appropriate control organism(s) to check the procedure. c) The results for the control organism(s) must be within established limits before reporting patient results. d) The laboratory must document all control procedures performed.</p>	<p>Appropriate control strains (QC strains) for antifungal susceptibility testing of yeasts include <i>Candida parapsilosis</i> ATCC 22019 and <i>Candida krusei</i> ATCC 6258 using the NCCLS 27-A guidelines. Other strains where QC ranges have been previously described in peer-reviewed journal may be used.</p> <p>Recent publications from NCCLS document (M27-A, M38-A, M27-A2, and M23-A2) describe daily or weekly quality control standards.</p>
DISK DIFFUSION METHODS	
<p>Mycology Standard 13 (MY S13)</p> <p>Each batch of media used for antifungal susceptibility testing by disk diffusion shall be checked for the expected zone size using known reference organisms before or concurrent with initial use.</p>	
<p>Mycology Standard 14 (MY S14)</p> <p>When using the disk diffusion method, the laboratory shall check each new lot of antifungal agents for the expected zone size using known reference organisms before or concurrent with initial use</p>	<p>The relevant literature is available in the NCCLS document M27-A2.</p>

Microbiology Mycology

Standard	Guidance
MACRODILUTION TUBES, MICRODILUTION PLATES, OR AGAR DILUTION PLATES METHODS	
<p>Mycology Standard 15 (MY S15)</p> <p>Before or concurrent with initial use, each batch of macrodilution tubes, microdilution plates, or agar dilution plates used for antifungal susceptibility testing shall be checked for MIC values that fall within range using appropriate control strains.</p>	<p>Antifungal standards or reference powders should not be from pharmacy stock or other clinical preparations.</p>
<p>Mycology Standard 16 (MY S16)</p> <p>For each reference organism, the MIC determined by the laboratory shall be verified as consistent with expected values or the run shall be deemed invalid.</p>	<p>All QC data shall be recorded.</p>
<p>Mycology Standard 17 (MY S17)</p> <p>For susceptibility testing, standardization of inoculum for both QC strains and test organisms shall be performed using one of the following methods:</p> <p style="padding-left: 40px;">Spectrophotometer with sterile cuvettes; MacFarland Standards for inoculum preparation; or Hemocytometer.</p>	<p>A number of publications describe interlaboratory validation of inoculum preparation by a variety of methods.</p>
<p>Mycology Standard 18 (MY S18)</p> <p>Each broth dilution series shall include a growth control of basal medium without antifungal agent to assess viability of the test organisms.</p>	<p>Series that fail to show viability of the test organism should be repeated.</p>

Microbiology Mycology

Standard	Guidance
<p>Mycology Standard 19 (MY S19)</p> <p>Susceptibility testing shall be performed on pure cultures.</p>	<p>A sample of each inoculum should be streaked on a suitable agar plate and incubated overnight. This plate will also provide freshly isolated colonies in the event retesting proves necessary.</p>
<p>Mycology Standard 20 (MY S20)</p> <p>Laboratories holding this category shall maintain a commercial system for detection of fungal antigen.</p>	<p>Cryptococcal antigen detection systems include Meridian Diagnostics Cryptococcal Latex Agglutination system (CALAS®), Meridian Diagnostics Premier™ Cryptococcal Antigen, Remel Cryptococcus Antigen Latex Test, Wampole Crypto-LA® Test, Immuno-Mycologics Latex-Cryptococcus.</p>

Microbiology Parasitology

Standard	Guidance
<p>The following specialty sustaining standards of practices shall be incorporated into the laboratory's quality management system, where applicable to the scope of services provided.</p>	
<p>Parasitology Standard 1 (PS S1)</p> <p>Reports on stool specimens shall:</p> <ul style="list-style-type: none"> a) include the methodology(ies) used; and, b) indicate whether or not a diagnostic test for <i>Cryptosporidium parvum</i> was performed. 	<p>Methodologies might include wet mount, permanent stains (such as trichrome and modified acid-fast), ELISA, MFA, etc.</p>
<p>Parasitology Standard 2 (PS S2)</p> <p>The laboratory shall have the ability to test for all reportable parasites.</p>	<p>Reportable parasites and acceptable diagnostic tests include:</p> <p><i>Cryptosporidium parvum</i> - Enzyme ImmunoAssay (EIA), Fluorescent Antibody (FA), <i>Cyclospora cayetanensis</i> - AF, Safranin <i>Entamoeba histolytica</i>—wet mount, Iron Haematoxylin (IH), Trichrome <i>Giardia duodenalis</i> - wet mount, FA, EIA, IH, Trichrome <i>Plasmodium falciparum</i> - Giemsa or Wright's blood stain <i>Taenia</i> species, <i>Trichinella spiralis</i>, <i>Enterobius vermicularis</i> - ova, whole mount</p>
<p>Parasitology Standard 3 (PS S3)</p> <p>The parasitology laboratory shall use an acid-fast stain when reporting of <i>Isoospora belli</i>.</p>	<p>The following stains or tests are recommended but not required for a Parasitology permit:</p> <p>Modified Trichrome Stain - for microsporidia (now classified as a fungus).</p>

Microbiology Parasitology

Standard	Guidance
<p>Parasitology Standard 4 (PS S4)</p> <p>For positive stool specimens, the laboratory shall retain, for a minimum of one year:</p> <ul style="list-style-type: none"> a) permanently stained slides; or, b) a portion of the sample, properly preserved and stored. 	<p>The staining method used is the choice of the laboratory, but the stain should be appropriate for the organism. Common permanent stains include modified acid-fast, trichrome, and iron hematoxylin.</p>
<p>Parasitology Standard 5 (PS S5)</p> <p>Permanent stains shall be checked using a positive and negative control, as a minimum, with each new shipment or lot, and once per month of use.</p>	<p>Controls may be obtained commercially or the laboratory may use validated patient or proficiency testing specimens.</p>
<p>Parasitology Standard 6 (PS S6)</p> <p>Each antigen detection kit shall be tested with at least one known positive and one known negative control each time the test is performed.</p>	
<p>Parasitology Standard 7 (PS S7)</p> <p>A calibrated ocular micrometer shall be:</p> <ul style="list-style-type: none"> a) used for determining the size of ova and parasites, where size is a critical factor; and; b) calibrated at least annually and each change in optics; and c) checked for each person using the microscope to insure consistency of results. 	<p>The SOPM should contain instructions for calibration, figures to show how each objective (high, oil, and low) has been calibrated, criteria for the use of the micrometer for determining the size of the ova and parasites and the maximum amount of variation acceptable between users of the microscope before individual calibration figures should be used.</p> <ul style="list-style-type: none"> c) The calibration figures should be checked for each new person hired.

Microbiology Parasitology

Standard	Guidance
<p>Parasitology Standard 8 (PS S8)</p> <p>Blood films for malaria shall meet the laboratory's pre-established criteria.</p>	<p>Giemsa stain is recommended; however, Wright's stain or a Wright-Giemsa combination stain may also be used. Controls are generally not available for this staining, but the laboratory should check the quality and preparation of its differential smears. An adequate number of fields [e.g., 300 oil immersion (10x100)] should be examined under oil immersion. Specimen collection time should be indicated on the report. If a single sample is submitted for testing, reports should also indicate that one negative specimen does not rule out the possibility of a parasitic infection.</p>
<p>Parasitology Standard 9 (PS S9)</p> <p>Fresh stool specimens shall:</p> <ul style="list-style-type: none"> a) be examined immediately after collection or preserved; and, b) not be refrigerated for more than three hours without proper fixation. 	<p>The laboratory should choose the fixative that is most appropriate for its testing purposes.</p>
<p>Parasitology Standard 10 (PS S10)</p> <p>A current reference collection of slides, photographs, or gross specimens of identified parasites shall be readily available in the laboratory for comparison with diagnostic specimens.</p>	<p>Textbooks with photographs, previously stained slide preparations, preserved specimens, or slides from proficiency testing programs are examples of acceptable reference material.</p>

Microbiology Parasitology

Standard	Guidance
<p>Parasitology Standard 11 (PS S11)</p> <p>The parasitology laboratory shall have available all the appropriate reagents, stains, and controls which are required to perform the procedures offered by the laboratory.</p>	<p>If the laboratory uses zinc sulfate for the concentration of fecal specimens, the specific gravity of the solution should be determined (1.18 for fresh specimens and 1.20 for formalin fixed specimens).</p> <p>Concentration is highly recommended.</p> <p>Direct microscopic exam (wet mounts) of fecal specimens may include both saline and iodine preparations. If iodine is used, the iodine solution should be that of D'Antoni's or Dobell and O'Connor (1%), or a 1:5 dilution of Lugol's iodine. Full strength Gram's iodine is not acceptable. A mechanism should exist to ensure that the iodine solution in use has not deteriorated.</p>

Microbiology Virology

Standard	Guidance
<p>These standards apply to conventional tube culture and to centrifugation-enhanced rapid methods unless otherwise specified.</p> <p>All laboratories performing viral culture using conventional tube cultures and/or rapid culture modifications (e.g. shell vials), shall additionally comply with the applicable requirements contained in the General Systems Standards and with designated Microbiology Standards.</p>	
<p>The following specialty sustaining standards of practices shall be incorporated into the laboratory's quality management system, where applicable to the scope of services provided.</p>	
<p>Virology Sustaining Standard of Practice 1 (VR S1): Cell Culture Systems</p> <p>The laboratory shall utilize cell cultures and methods appropriate for the isolation and/or detection of the viral agents specified in its test menu.</p>	<p>Several texts and resources are available including: CLSI M41-A, <u>26</u> (35): Viral Culture; Approved Guideline</p>
<p>Virology Sustaining Standard of Practice 2 (VR S2): Cell Culture Records</p> <p>The laboratory shall maintain records for each commercial cell culture lot received including: cell culture type and vendor; lot number; passage level (if appropriate); date of receipt; condition at the time of receipt including the percentage of monolayer confluence; and any corrective action taken for cell culture lots that are of questionable or unsatisfactory condition at the time of receipt. Similar records shall be maintained for cell cultures prepared in house.</p>	<p>The SOPM should include the criteria for assessing the quality of cell cultures at receipt (e.g. degree of monolayer confluence, adverse conditions such as cell rounding, detached monolayers, pH extremes or microbial contamination).</p> <p>Date of seeding rather than date of receipt should be recorded for cell cultures prepared in-house.</p>

Microbiology Virology

Standard	Guidance
<p>Virology Sustaining Standard of Practice 3 (VR S3): Cell Culture Shelf Life and Condition</p> <p>Cell cultures used for testing patient specimens shall be examined microscopically and confirmed for acceptability as defined in the SOPM on the day of inoculation and used within:</p> <ul style="list-style-type: none"> a) the expiration date, if provided by the vendor or b) 10 days after the monolayers become 100% confluent or c) 10 days of receipt, if monolayers were 100% confluent when received. 	<p>Slightly sub-confluent monolayers are optimal for viral culture. Crowded, overgrown, or aged cultures may result in decreased virus susceptibility.</p>
<p>Virology Sustaining Standard of Practice 4 (VR S4): Mycoplasma Screening of Cell Cultures</p> <p>Diploid and continuous cell lines shall be tested at least every 6 months for <i>Mycoplasma</i> contamination while the cell lines are in use.</p>	<p>Documentation by the vendor that the cells are free of mycoplasma contamination is acceptable for commercially supplied cell lines.</p>
<p>Virology Sustaining Standard of Practice 5 (VR S5): Cell Culture Medium</p> <p>The laboratory shall maintain records for each lot of cell culture maintenance and growth medium including the type, vendor, lot number and the receipt and expiration dates. Similar records shall be maintained for culture media prepared in-house and for medium components added by the laboratory.</p>	<p>The type of medium refers to its formulation, e.g. Eagle's MEM with 2% FBS.</p>

Microbiology Virology

Standard	Guidance
<p>Virology Sustaining Standard of Practice 6 (VR S6): Cell Culture Medium Quality Control</p> <p>Quality control of cell culture medium shall be documented and minimally ensure that cell culture media have been tested for sterility and toxicity prior to use and have an acceptable pH at the time of use.</p>	<p>Documentation by the vendor that appropriate sterility, toxicity and other quality control testing has been performed on commercially supplied medium is acceptable. However, appropriate in-house testing must be performed if components are added by the laboratory.</p> <p>Sterility testing, if necessary, should be performed using bacterial culture techniques.</p> <p>Visual inspection to confirm an acceptable pH range for medium containing a colorimetric pH indicator is acceptable.</p> <p>The possibility of viral inhibition by a medium component (e.g. serum) should be considered and investigated if there is evidence to suggest a decrease in viral culture sensitivity.</p>
<p>Virology Sustaining Standard of Practice 7 (VR S7): Biological Safety Cabinet (BSC) Use</p> <p>A class II or higher BSC shall be used for inoculating cell cultures with clinical specimens and for all procedures involving the maintenance and processing of inoculated cell cultures and culture-amplified materials.</p>	<p>Refer to Safety Sustaining Standard of Practice 6 (SAF S6) for operational guidelines.</p>
<p>Virology Sustaining Standard of Practice 8 (VR S8): Specimen Processing Procedures</p> <p>The SOPM shall include specimen processing and inoculation procedures for each type (e.g. swab, tissue, blood) of specimen.</p>	<p>Processing procedures include dilution, fractionation, centrifugation, decontamination, homogenization or other treatments utilized for rendering specimens suitable for cell culture inoculation.</p> <p>Inoculation procedures primarily refer to inoculum volume and adsorption steps (if performed).</p>

Microbiology Virology

Standard	Guidance
<p>Virology Sustaining Standard of Practice 9 (VR S9): Cell Culture and Culture Medium Lot Numbers</p> <p>Dates of culture manipulations and microscopic observations shall be recorded on each specimen worksheet.</p>	<p>Culture manipulations include all processing steps such as inoculation, medium changes, subpassage and harvesting.</p> <p>This standard is consistent with the requirement for recreating the test process as stated in standards Quality Management System Sustaining Standard 1 (QMS S1)(t) and Reagents Sustaining Standard 4 (REAG S4).</p>

Microbiology Virology

Standard	Guidance
<p>Virology Sustaining Standard of Practice 10 (VR S10): Specimen Criteria</p> <p>The SOPM shall define the remedial action that may be employed for specimens that exhibit contamination or toxicity.</p>	<p>Remedial action for specimens causing adverse culture events (e.g. contamination, toxicity) may include reinoculation, sub-passage, filtration, recollection).</p>
<p>Virology Sustaining Standard of Practice 11 (VR S11): Viral Culture Criteria and Timepoints</p> <p>The SOPM shall define culture criteria including:</p> <ul style="list-style-type: none"> a) inoculation and incubation conditions (e.g. temperature); b) minimal culture duration; c) minimally acceptable culture observation and documentation schedules; d) maintenance/processing schedules (e.g. media changes, hemadsorption [HAd], staining); e) conditions that render a culture unacceptable or uninterpretable, including an unacceptable monolayer condition at completion (see Virology Sustaining Standard 21 (VR S21)). 	<ul style="list-style-type: none"> a) Inoculation includes specimen adsorption conditions, if applicable. c) Observation includes the microscopic examination of monolayers for evidence of cytopathic effect (CPE), toxicity and contamination. c) The minimal frequency for microscopically observing cultures and recording results is every other day during the first week of incubation and then every 2 to 3 days thereafter. c) Optimally, cultures should be observed on the first day after specimen inoculation in order to initiate timely remediation of adverse events (e.g. toxicity, contamination) and to detect rapidly growing agents. The SOPM should define exceptions and describe remedial action for handling of potentially compromised cultures.

Microbiology Virology

Standard	Guidance
<p>Virology Sustaining Standard of Practice 12 (VR S12): Negative Cell Culture Controls</p> <p>Uninoculated (negative) lot-matched cell culture controls shall be processed, incubated, maintained and observations recorded in parallel with patient specimens for the entire duration that each lot is in use.</p>	<p>Uninoculated (negative) controls are observed for evidence of unacceptable occurrences such as monolayer deterioration, CPE, HAd and other conditions that should not occur in uninoculated cell cultures. Troubleshooting and corrective action are based on adverse findings as described in the SOPM.</p> <p>Maintenance of controls in parallel with patient specimens requires that the same lot of cell culture medium being used for medium changes on patient specimens is used for the controls.</p> <p>When using centrifugation-enhanced rapid methods, processing includes the centrifugation step.</p> <p>The possibility that a defective lot of culture medium may be the source of deterioration or contamination in uninoculated (negative) controls should be considered. The need to repeat medium quality control testing should be determined (see Virology Sustaining Standard 6 (VR S6)).</p>

Microbiology Virology

Standard	Guidance
<p>Virology Sustaining Standard of Practice 13 (VR S13): Positive Live Virus Culture Controls</p> <p>Live virus-inoculated (positive) culture controls shall be employed as deemed necessary with the exception of genetically engineered cell lines where they shall be included for every run.</p>	<p>With the exception of genetically engineered cell lines, virus-inoculated (positive) culture controls need be employed only as necessary (e.g. suspected performance problems; assessing a new cell culture type or source; training and remediation activities). In lieu of the routine use of positive live virus controls, the laboratory should identify appropriate indicators that would be useful in identifying cell culture sensitivity problems (see Virology Sustaining Standard 20 (VR S20)).</p> <p>Virus-inoculated positive controls are included in every run when using genetically engineered cell lines to confirm the stability and activity of the transfected plasmid as well as the reactivity of the enzyme and substrate.</p> <p>Virus preparations used for inoculating positive controls should optimally consist of low-passage material derived from clinical isolates rather than laboratory-adapted strains and should be inoculated at a low multiplicity of infection (m.o.i).</p>
<p>Virology Sustaining Standard of Practice 14 (VR S14): RBC Suspensions</p> <p>The laboratory shall maintain records for each lot of red blood cells (RBC) used for viral detection/identification procedures and shall include the RBC type, vendor, lot number and date of expiration.</p>	
<p>Virology Sustaining Standard of Practice 15 (VR S15): RBC Controls for Hemadsorption (HAd) Assays</p> <p>RBC Controls in each HAd run shall include:</p> <ol style="list-style-type: none"> a) a negative control that is an uninoculated cell culture monolayer that is lot-matched to that used for patient specimens; and, b) at least one positive control per lot number of RBCs. 	<p>Negative RBC controls are intended to determine whether the RBCs react with uninoculated cell culture monolayers. Virology Sustaining Standard 12 (VRS S12) requires that negative HAd controls be performed in parallel with HAd assays performed on patient inoculated cell cultures.</p> <p>Positive RBC controls should confirm that the RBCs react in the expected manner with virus-inoculated monolayers.</p>

Microbiology Virology

Standard	Guidance
<p>Virology Sustaining Standard of Practice 16 (VR S16): Confirmation and Identification of Cultured Viruses</p> <p>Each run shall include a:</p> <ul style="list-style-type: none"> a) positive control; b) lot-matched negative (uninoculated) cell culture control. 	<ul style="list-style-type: none"> a) The positive control is intended to confirm detection system reactivity. This standard does not require the positive control to be lot-matched to patient specimens and allows the use of appropriate commercial controls. The optional use of lot-matched virus-inoculated positive controls would serve to monitor cell culture sensitivity. If live virus preparations are used for inoculating positive controls, they should optimally consist of low-passage material derived from clinical isolates rather than laboratory-adapted material and should be inoculated at a low m.o.i. b) The negative cell culture control reveals background or non-specific reactivity of the detection system and serves to assist with reading. Using lot-matched uninoculated cells (see Virology Sustaining Standard 12 (VR S12)) also serves to identify problems that may be associated with the specific lot of cell cultures used for specimen inoculation. <p>When using an indirect antibody staining format, additional controls may be incorporated to rule out reactivity of the conjugate (labeled secondary antibody) with the cell substrate. Alternatively, these may be utilized as needed for troubleshooting purposes if, for example, the negative control (b) yields positive or unacceptable results. In this case, diluent or an irrelevant antibody would be substituted for the primary unlabeled antibody.</p>

Microbiology Virology

Standard	Guidance
<p>Virology Sustaining Standard of Practice 17 (VR S17): Viral Neutralization and Hemagglutination-Inhibition (HI) Assays</p> <p>For neutralization and HI assays, the laboratory shall:</p> <ul style="list-style-type: none"> a) use an established optimal concentration of antibodies or antisera; and, b) use the proper concentration (e.g. TC_{ID50} or hemagglutinating units) of test and control viruses. 	<p>Optimal concentrations of control virus material and antibody preparations may need to be re-established or confirmed with prolonged storage. Repeated freeze-thaw cycles should be avoided.</p>
<p>Virology Sustaining Standard of Practice 18 (VRS18): Viral Neutralization and Hemagglutination-Inhibition (HI) Assay Controls</p> <p>For neutralization and HI assays, the laboratory shall include appropriate controls in each run (e.g. matched virus-antibody control; virus-diluent control; unmatched virus-antibody control; RBC controls; viral dose control).</p>	
<p>Virology Sustaining Standard of Practice 19 (VR S19): Rapid Centrifugation-enhanced Virus Culture Methods</p> <p>The laboratory shall:</p> <ul style="list-style-type: none"> a) perform centrifugation using closed or sealed buckets or rotor; b) include in the SOPM the speed required to achieve the appropriate g-force for each type of rotor in use and record the centrifuge speed setting at the beginning of each run; c) include in the SOPM the acceptable temperature range for the centrifugation step. 	<ul style="list-style-type: none"> c) Temperature-controlled centrifuges are preferred for these procedures. Laboratories not using a temperature-controlled centrifuge should be aware of the potential for detrimental effects on culture monolayers and culture sensitivity resulting from over-heating of the centrifuge chamber. Laboratories using temperature-controlled centrifuges should not begin culture centrifugation until an appropriate temperature has been reached.

Microbiology Virology

Standard	Guidance
<p>Virology Sustaining Standard of Practice 20 (VR S20): Viral Culture Performance Monitoring</p> <p>The laboratory shall monitor key indicators of viral culture performance as defined in the QA Program and shall review these monthly and implement timely troubleshooting and remediation activities as necessary.</p>	<p>Appropriate key indicators of viral culture performance should be selected based on the scope of testing and the methods performed by the laboratory. Examples include: unacceptable observations/results with negative and positive controls; unanticipated variations in isolation rates; discrepancies between different methods; discrepancies with results obtained by other laboratories; shift or staff-related performance variations; rate of unsatisfactory or incomplete specimens; and, rate of contaminated specimens.</p>
<p>Virology Sustaining Standard of Practice 21 (VR S21): Reporting Criteria</p> <p>Reports shall include qualifiers for cultures:</p> <ul style="list-style-type: none"> a) that are incomplete or uninterpretable; b) which the isolate identification is considered presumptive, i.e. an isolate is not confirmed by a specific viral identification system. 	<ul style="list-style-type: none"> a) A viral culture result cannot be interpreted as negative unless at least 50% of the expected area of monolayer coverage is still present (on the side of the tube, surface of the coverslip, or bottom of the well) and is of normal morphology at the end of the minimal incubation period (See Virology Sustaining Standard 11 (VR S11)). Negative culture results should include a qualifier in cases where optimal specimen transport time/conditions have not been met. b) Specific viral identification systems include immunologic or nucleic acid detection assays as well as genetically engineered cell line systems designed for the detection of viral agents.